Candidate Genes of Allergic Dermatitis Are Associated with Immune Response

Lei Jin,1,2 Lin Deng,3 and Wanchun Wang4

1Doctor Class of 2021, Jiangxi University of Chinese Medicine, Nanchang 330000, Jiangxi, China
2Department of Dermatology, Shanghai Hudong Hospital, Shanghai 200000, China
3Department of Trauma Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China
4Department of Traditional Chinese Medicine Surgery, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang 330000, Jiangxi, China

Correspondence should be addressed to Wanchun Wang; wangwanchun@jxszyy.org.cn

Received 11 November 2021; Revised 3 December 2021; Accepted 9 December 2021; Published 4 January 2022

Academic Editor: Bhagyaveni M.A

Allergic dermatitis (AD) is a common and burdensome inflammatory skin disease, and diagnosis is challenging. This study was conducted to identify candidate genes for AD diagnosis and underlying molecular mechanisms. Gene expression profiles were obtained from datasets GSE121212, GSE130588, and GSE157194. Use differential analysis to identify differentially expressed genes (DEGs) between AD and control. Use enrichment analysis to identify potential molecular dysregulation mechanisms. Comprehensive least absolute shrinkage and selection operator (LASSO) logistic regression, receiver operator characteristic (ROC) curve, and logistic regression analysis are used to identify candidate genes. In addition, ssGSEA and ImmPort database were used to identify AD-related immune response abnormalities. In this study, a total of 60 common genes were identified. Enrichment analysis found that these genes are mainly involved in T helper cell immune and complement and coagulation cascades. LASSO regression analysis identified 18 feature genes, and screened genes with AUC > 0.75 were selected as candidate genes. Finally, PLA2G4D, IFI6, AGR3, IGFL1, SPRR3, ATP13A5, SERPINB13, KRT16, HAS3, and CH25H were recognized as candidate genes and maybe able to diagnose AD. PLA2G4D, CH25H, and IFI6 may be risk factors for AD based on logistic analysis. Furthermore, we identified the abnormalities of immune response activation in AD patients. Interestingly, PLA2G4D, CH25H, and IFI6 had positive correlations with immune cells and signaling pathways. PLA2G4D, CH25H, and IFI6 may be candidate diagnostic genes for AD. This may be related to their promotion of abnormal immune activation, especially T helper cell immune.

1. Introduction

Allergic dermatitis (AD) is an inflammatory skin disease caused by skin contact with various allergens in the external environment [1]. Studies have shown that AD often occurs in children, with an incidence rate of 15–20%. Among adults, the incidence rate is 1–3%. In recent years, the incidence rate has increased by 2-3 times [2]. Common symptoms of AD patients are erythema, edema, papules, blisters, bullae, and even necrosis, accompanied by varying degrees of itching, pain, or burning [3, 4]. Children are common on the cheeks, and adult patients are common on the folds of the joints and on the back of the hands or on the scalp [5, 6].

AD is related to the combined effects of heredity, environment, immunity, and other factors and has an obvious familial genetic tendency. Studies have reported some susceptible areas on chromosomes [7]. Currently, it is believed that various internal and external factors act on the immune cells of the body, including immune cells fixed in the skin and other nonfixed immune cells that dynamically enter the skin, causing immune abnormalities and ultimately leading to the occurrence of AD [8]. The occurrence of AD is related to disease factors, such as asthma, hay fever, allergic rhinitis,
and food allergies [9]. Meanwhile, studies have found that the expression of IgE is significantly increased in AD patients, and the level of IgE is significantly correlated with the severity of the disease [10].

So far, the diagnosis of AD is still based on its clinical symptoms, and no experimental diagnosis has become the gold standard for clinical diagnosis. Different countries or regions adopt different diagnostic criteria, and scholars are constantly revising and improving the diagnostic criteria, but the Hanifin and Rajka criteria and the Williams diagnostic criteria are still more commonly used [11, 12]. However, due to the complicated clinical manifestations of AD and more family history and concomitant diseases, the results of skin prick tests and total IgE levels are often inconsistent, and this method requires subjective judgment and is poor in reproducibility. Moreover, the aforementioned diagnostic methods cannot be effectively used as an early warning for the occurrence of AD.

Up to now, researchers have conducted a lot of analyses and testing on AD. However, no effective diagnostic method has been identified. It is of great significance to seek superior diagnostic targets and establish diagnostic methods for the treatment and prevention of AD patients. Therefore, this study reanalyzes the differential genes of AD patients in the existing GSE121212, GSE130588, and GSE157194 databases in order to provide valuable genetic targets for future AD diagnosis and research.

2. Materials and Methods

2.1. Data Collection. GSE121212, GSE130588, and GSE157194 datasets were downloaded from the Gene Expression Omnibus (GEO) database. The GSE121212 dataset included gene expression profiles of skin tissue from 27 AD patients and 38 healthy controls based on high throughput sequencing. The GSE130588 dataset included gene expression profiles of 42 lesional skin from AD patients and 38 nonlesional controls based on GPL570. The GSE157194 dataset included gene expression profiles of 57 lesional skin from AD patients and 54 nonlesional controls based on high throughput sequencing.

2.2. Difference Analysis. The differential analysis of gene expression between AD and controls was performed using DESeq2 R software package [13] for GSE121212 and GSE157194 datasets or limma R software package [14] for the GSE130588 dataset. Differentially expressed genes (DEGs) were then obtained by setting screening threshold with \( \log_{2}[|FC|] > 1 \) and \( P < 0.05 \). Furthermore, we identified the intersection genes of the three sets of DEGs as common genes.

2.3. Enrichment Analysis. The enrichment analysis of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) for common genes was performed using clusterProfiler R package [15]. The \( P \) value <0.05 was considered significantly enriched.

2.4. Screening of Key Genes. The least absolute shrinkage and selection operator (LASSO) logistic regression was performed to primarily select feature genes using glmnet R package. The optimal \( \lambda \) was chosen corresponding to minimum cross-validation error. The variables were eliminated, ultimately retaining potential genes with nonzero coefficients. Then, receiver operator characteristic (ROC) curve was plotted, and area under the ROC curve (AUC) was calculated to evaluate the diagnostic role of feature genes. The logistic regression analysis was performed to draw forest plots.

2.5. Calculation of the Immune Score. The marker genes for immune cell types were obtained from Bindea et al. [16]. The infiltration level of immune cell type was calculated using single-sample gene set enrichment analysis (ssGSEA) by GSVA R software package. The immune-related pathways were obtained from the ImmPort database.

3. Results

3.1. Differentially Expressed Genes in AD. In order to identify abnormally expressed genes related to AD, we performed a differential expression analysis of AD and control genes. In the GSE121212 dataset, we have identified 4651 DEGs (Figure 1(a)). We have identified 554 DEGs in the GSE130588 dataset (Figure 1(b)). We identified 1962 DEGs in the GSE157194 dataset (Figure 1(c)). Among them, we obtained a total of 60 common genes (Figure 1(d)). The expression of common genes in AD and control is significantly different, and they may be abnormally expressed genes related to AD (Figure 1(e)).

3.2. Enrichment Analysis of Common Genes. In order to identify the potential molecular dysregulation mechanism of AD, we performed enrichment analysis on common genes. The GO results (Figure 2(a)) suggested that defense response to bacterium, negative regulation of endopeptidase activity, and negative regulation of peptidase activity of biological processes (BP) were mainly enriched by common genes. The secretory granule lumen, cornified envelope, and specific granule lumen of the cellular components were also enriched. As well as serine-type endopeptidase inhibitor activity, endopeptidase inhibitor activity, and RAGE receptor binding of molecular function were mainly enriched. In addition, the IL-17 signaling pathway, Th17 cell differentiation, and complement and coagulation cascades of KEGG pathways were mainly signature enriched by common genes (Figure 2(b)).

3.3. Candidate Genes of AD. In order to identify diagnostic candidate genes that can predict the occurrence of AD, we performed LASSO regression analysis on common genes. Based on the best \( \lambda \) value, we identified 18 feature genes could predict AD most accurately (Figures 3(a) and 3(b)). The AUC values for feature genes were calculated and found the AUC values were greater than 0.5 (Figures 3(c)–3(e)).
Figure 1: Continued.
Among GSE121212, GSE130588, and GSE157194 datasets, the genes with AUC > 0.75 were selected as candidate genes (Figure 3(f)). Finally, PLA2G4D, IFI6, AGR3, IGFL1, SPRR3, ATP13A5, SERPINB13, KRT16, HAS3, and CH25H were recognized as candidate genes and may be able to diagnose AD.

According to the logistic regression analysis results, we found that PLA2G4D, CH25H, and IFI6 were risk factors in all GSE121212, GSE130588 and GSE157194 datasets (Figure 4).

3.4. Immune Cells and Pathways in AD. To identify the infiltration of immune cells in AD patients, we analyzed the expression of marker genes for immune cells in AD and controls. The results found that there is a significant difference in the level of immune cell infiltration between AD and control (Figures 5(a)–5(c)). By comparing the activation differences of immune-related signaling pathways between AD and control, we also identified abnormal pathways in AD (Figures 5(d)–5(f)). This further suggests that there are a large number of abnormal immune responses in AD patients. Subsequently, we conducted correlation analysis to evaluate the relationship between candidate genes and immune cells and signaling pathways. There is a positive correlation between PLA2G4D, CH25H, and IFI6 and the level of immune cell infiltration (Figure 6(a)). PLA2G4D, CH25H, and IFI6 are also positively correlated with the activation of immune-related signaling pathways (except for TGFβ family member and TGFβ family member receptor) (Figure 6(b)). This suggests that PLA2G4D, CH25H, and IFI6 as risk factors for AD may be related to the promotion of immune activation.

4. Discussion

In this study, we identified 60 common genes in the GSE121212, GSE130588, and GSE157194 databases. Through analysis, we finally determined that PLA2G4D, CH25H, and IFI6 can be used as candidate genes for AD diagnosis. Further studies have shown that PLA2G4D, CH25H, and IFI6 are related to the level of immune cell infiltration and the activation of immune-related signal pathways.

In the past few decades, researchers have conducted a lot of analysis on the occurrence of AD, which has important implications for the diagnosis, prevention, and treatment of AD. At the same time, the occurrence of AD is accompanied by changes in gene function and forms a complex network of effects. This also provides a unique opportunity for the detection methods and systems for the diagnosis and prevention of AD. However, researchers have done a lot of analysis on the differential genes when AD occurs [17]. Up to now, there are still no specific detection markers and detection methods for AD. Therefore, the reanalysis of previous studies may give us a new understanding of the
Figure 2: The GO and KEGG pathways enriched by common genes. (a) Top 10 biological functions of common genes significantly enriched. The BP, CC, and MF included in GO enrichment. (b) KEGG signaling pathways with significant involvement of common genes.
Figure 3: Continued.
Figure 3: The LASSO regression prediction model based on common genes. (a) Selection of parameter (λ) in the LASSO model according to optimal criteria. (b) Construction of LASSO model using 18 feature genes and their coefficients. The ROC curves of 18 feature genes in GSE121212 (c), GSE130588 (d), and GSE157194 (e) datasets predicting the occurrence of AD. AUC, area under ROC curve. (f) Intersection of feature genes with AUC >0.75 in GSE121212, GSE130588, and GSE157194 datasets.

| Var      | OR (95% CI)  | P value |
|----------|--------------|---------|
| KRT16    | -1.01 (-2.4~0.19) | 0.119 |
| SPRR3    | -0.71 (-2.21~0.66) | 0.319 |
| AGR3     | -0.29 (-0.65~0.04) | 0.096 |
| ATP13A5  | -0.18 (-0.94~0.52) | 0.615 |
| IGFL1    | 0.17 (-0.31~0.65) | 0.485 |
| CH25H    | 0.29 (-0.65~1.26) | 0.546 |
| SERPINB13| 0.43 (-0.44~1.4) | 0.351 |
| IF6      | 0.56 (-0.14~1.39) | 0.142 |
| PLA2G4D  | 1.15 (0.25~2.19) | 0.017 |
| HAS3     | 2.19 (0.95~3.82) | 0.002 |

Figure 4: Continued.
Figure 4: The forest plots of candidate genes in GSE121212, GSE130588, and GSE157194 datasets.

Figure 5: Continued.
mechanism of AD. In our analysis, we identified a total of 60 common genes. The analysis of these genes may have a reference value for the diagnosis of AD in the future.

On further analysis of these common genes, we found the significantly enriched IL-17 signaling pathway and cell differentiation signaling pathway. Current research shows that IL-17 is a type of cytokine produced by Th17 cells [18]. IL-17 can induce the production of proinflammatory cytokines, chemokines, and antimicrobial peptides [19]. At the same time, Th17 cells and cytokine IL-17 are also involved in allergic diseases [20]. IL-17 antagonists have been approved to treat patients with psoriasis [21]. In studies on AD, patients with AD and children have significantly higher levels of Th17 cells and IL-17 in peripheral blood [22]. Subsequently, Nick et al. showed that it was proved that the type of IL-17, IL-17C, is the central mediator of AD [23]. This also further suggests the role of the IL-17 signaling pathway in the occurrence of AD.
Through further analysis, we finally determined that PLA2G4D, CH25H, and IFI6 can be used as potential detection targets for AD. CH25H is a rate-limiting enzyme, which mainly plays a rate-limiting role in the synthesis of oxysterol 7α, 25-dihydroxycholesterol from cholesterol [24]. Studies have shown that CH25H can exert its anti-inflammatory function by activating CD44+ CD4+ T cells to migrate to inflamed tissues [25]. Michael’s research shows that the imbalance of CH25H expression can lead to chronic inflammation and cancer [26]. However, CH25H has no effect on the expression of IL-17 [27]. In the study of Vittorio et al., CH25H can be used as a diagnostic marker to distinguish allergic and irritant contact dermatitis [27]. PLA2G4D and IFI6 have been identified as biomarkers of psoriasis [28, 29]. Meanwhile, PLA2G4D can induce the expression of IL-17 [28]. The expression level of IFI6 is also closely related to the inflammatory response [30]. In addition, we found that PLA2G4D, CH25H, and IFI6 are related to the activation of immune-related signal pathways and immune cell infiltration.

5. Conclusion
In related studies, PLA2G4D and IFI6 are highly expressed in immune cells that infiltrate tissues [28, 31]. It is closely related to the infiltration of mast cells in inflamed tissues [31]. This also further shows that the occurrence of AD is closely related to immune infiltration.

In summary, our results indicate that the occurrence of AD is related to abnormal immune activation. In addition, PLA2G4D, CH25H, and IFI6 can be used as biomarkers of AD.

Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.
Acknowledgments

The work was supported by “construction of the comprehensive reform test zone of National Traditional Chinese Medicine Development of Symbol District” in 2020 project (PDZY-2020-0404).

References

[1] D. Wallach and A. Täib, "Atopic dermatitis/atopic eczema," History of Allergy, vol. 100, pp. 81–96, 2014.
[2] M. I. Asher, S. Monteferot, B. Björksten et al., "Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys," The Lancet, vol. 368, no. 9537, pp. 733–743, 2006.
[3] Z. C. Chiesa Fuxench, "Atopic dermatitis: disease background and risk factors," Advances in Experimental Medicine & Biology, vol. 1027, pp. 11–19, 2017.
[4] N. K. Gaspar and M. K. Aidé, "Atopic dermatitis: allergic dermatitis or neuroimmune dermatitis?" Anais Brasileiros de Dermatologia, vol. 91, no. 4, pp. 479–488, 2016.
[5] H. Ohitsu and M. Selke, "Histamine and histamine receptors in allergic dermatitis," Handbook of Experimental Pharmacology, vol. 241, pp. 333–345, 2017.
[6] D. Ghosh, J. A. Bernstein, G. K. Khurana Hershey, M. E. Rothenberg, and T. B. Mersha, "Leveraging multilayered "omics" data for atopic dermatitis: a road map to precision medicine," Frontiers in Immunology, vol. 9, p. 2727, 2018.
[7] D. A. Plager, S. M. Torres, S. N. Koch, and H. Kita, "Gene transcription abnormalities in canine atopic dermatitis and related human eosinophilic allergic diseases," Veterinary Immunology and Immunopathology, vol. 149, no. 1-2, pp. 136–142, 2012.
[8] K. Breuer, T. Werfel, and A. Kapp, "Allergic manifestations of skin diseases - atopic dermatitis," Allergy and Asthma in Modern Society: A Scientific Approach, vol. 91, pp. 76–86, 2006.
[9] C. Favrot, A. Rostaher, and N. Fischer, "Klinische merkmale, diagnose und therapie des feline atop syndroms," Schweizer Archiv für Tierheilkunde, vol. 156, no. 7, pp. 327–335, 2014.
[10] J. J. Lyons, J. D. Milner, and K. D. Stone, "Atopic dermatitis in children," Immunology and Allergy Clinics of North America, vol. 35, no. 1, pp. 161–183, 2015.
[11] K. Maliyar, C. Sibbald, E. Pope, and R. Gary Sibbald, "Diagnosis and management of atopic dermatitis: a review," Advances in Skin & Wound Care, vol. 31, no. 12, pp. 538–550, 2018.
[12] H. C. Williams, P. G. Jburney, R. J. Hay et al., "The U.K. working party’s diagnostic criteria for atopic dermatitis," British Journal of Dermatology, vol. 131, no. 3, pp. 383–396, 1994.
[13] M. I. Love, W. Huber, and S. Anders, "Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2," Genome Biology, vol. 15, no. 12, p. 550, 2014.
[14] M. E. Ritchie, B. Phipson, D. Wu et al., "Limma powers differential expression analyses for RNA-sequencing and microarray studies," Nucleic Acids Research, vol. 43, no. 7, p. e47, 2015.
[15] G. Yu, L.-G. Wang, Y. Han, and Q.-Y. He, "clusterProfiler: an R package for comparing biological themes among gene clusters," OMICS: A Journal of Integrative Biology, vol. 16, no. 5, pp. 284–287, 2012.
[16] G. Bindea, B. Melecni, M. Tosolini et al., "Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer," Immunity, vol. 39, no. 4, pp. 782–795, 2013.
[17] L. Möbus, E. Rodriguez, I. Harder et al., "Atopic dermatitis displays stable and dynamic skin transcriptome signatures," The Journal of Allergy and Clinical Immunology, vol. 147, no. 1, pp. 213–223, 2021.
[18] P. Miossec and J. K. Kolls, "Targeting IL-17 and TH17 cells in chronic inflammation," Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 763–776, 2012.
[19] K. Bunte and T. Beikler, "Th17 cells and the IL-23/IL-17 Axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases," International Journal of Molecular Sciences, vol. 20, no. 14, 2019.
[20] K. Oboki, T. Ohno, H. Saito, and S. Nakae, "Th17 and allergy," Allergy International, vol. 57, no. 2, pp. 121–134, 2008.
[21] E. Topal, T. Zubberbier, M. P. Makris, and M. Hofmann, "The role of IL-17, IL-23 and IL-31–IL-33 in allergic skin diseases," Current Opinion in Allergy and Clinical Immunology, vol. 20, no. 4, pp. 367–373, 2020.
[22] Q. Tan, H. Yang, E. Liu, and H. Wang, "P38/ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL-17," Molecular Medicine Reports, vol. 16, no. 6, pp. 8863–8867, 2017.
[23] N. Vandeghinste, J. Klattig, C. Jagerschmidt et al., "Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis," Journal of Investigative Dermatology, vol. 138, no. 7, pp. 1555–1563, 2018.
[24] W.-S. Choi, G. Lee, W.-H. Song et al., "The CH25H-CYP7B1-RO2a axis of cholesterol metabolism regulates osteoarthritis," Nature, vol. 566, no. 7743, pp. 254–258, 2019.
[25] F. Chalmin, V. Rochemont, C. Lippens et al., "Oxysterols regulate encephalitogenic CD4+ T cell trafficking during central nervous system autoimmunity," Journal of Autoimmunity, vol. 56, pp. 45–55, 2015.
[26] M. E. Abrams, K. A. Johnson, S. S. Perelman et al., "Oxysterols provide innate immunity to bacterial infection by mobilizing cell surface accessible cholesterol," Nature Microbiology, vol. 5, no. 7, pp. 929–942, 2020.
[27] V. Fortino, L. Wisgrill, P. Werner et al., "Machine-learning-driven biomarker discovery for the discrimination between allergic and irritant contact dermatitis," Proceedings of the National Academy of Sciences, vol. 117, no. 52, pp. 33474–33485, 2020.
[28] K. L. Cheung, R. Jarrett, S. Subramaniam et al., "Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1d," Journal of Experimental Medicine, vol. 213, no. 11, pp. 2399–2412, 2016.
[29] Y. J. Zhang, Y. Z. Sun, X. H. Gao, and R. Q. Qi, "Integrated bioinformatic analysis of differentially expressed genes and signaling pathways in plaque psoriasis," Molecular Medicine Reports, vol. 20, no. 1, pp. 225–235, 2019.
[30] X. Pang, X. Li, Z. Mo et al., "IFI16 is involved in HBV-associated acute-on-chronic liver failure inflammation," BMC Gastroenterology, vol. 18, no. 1, p. 61, 2018.
[31] M. Xiang, Q. Chen, Y. Feng et al., "Bioinformatic analysis of key biomarkers and immune filtration of skin biopsy in discoid lupus erythematosus," Lupus, vol. 30, no. 5, pp. 807–817, 2021.